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Introduction
Early pregnancy factor (EPF) is a secreted protein with
immunosuppressive and growth factor properties. It was first
described in mice as a factor appearing in maternal serum
within 24 h of fertile mating.1 Subsequently, it has been
shown to be present in all mammalian species studied, per-
sisting for at least the first two-thirds of pregnancy (reviewed
by Morton2). Like other cytokines and growth factors, EPF
has pleiotropic effects.
Early pregnancy factor was first shown to have an
immunomodulatory role with the demonstration that it could
suppress the adoptive transfer of contact sensitivity to tri-
nitrochlorobenzene from sensitized mice to naïve, syngeneic
mice.3,4 This assay is a measure of the delayed-type hyper-
sensitivity (DTH) response and is evidence that EPF sup-
presses Th1 responses. Further evidence has been provided
by its ability to suppress phytohaemagglutinin-induced 
stimulation of mouse spleen cells.2 Early pregnancy factor
modulates the DTH response by stimulation of downregula-





, from both mouse and human lymphocytes.5,6 This
suggests that EPF can initiate a cascade reaction and that
some of the immunomodulatory effects of EPF are down-
stream from initial EPF binding event.
In addition to immunomodulatory effects, we have also
found that EPF plays a role in cell growth and survival. Early
pregnancy factor is essential for the embryo during normal
development7,8 and for tissue renewal, as shown in liver
regeneration following partial hepatectomy.9 As well as a role
in normal cell proliferation, EPF also acts as an autocrine
growth factor for tumour cells.10
We have now identified EPF as a homologue of chaper-
onin 10 (Cpn10),11 a heat shock protein (hsp) found in mito-
chondria.12 Chaperonin 10 and EPF differ in functional
targets and mechanisms of action. Chaperonin 10 specifically
interacts with chaperonin 60 within the cell to facilitate
correct folding of a variety of protein targets,12 whereas we
have shown that EPF has extracellular cytokine-like activities
as described earlier. Despite amino acid sequence identity
between the human EPF and Cpn10 proteins,13 recent studies
(BH Fletcher et al. unpubl. data, 2000) suggest that they are
encoded by different genes.
Further studies of the in vivo function of EPF have been
difficult to undertake, because only insignificant quantities
of EPF could be obtained from natural sources. We have now
prepared recombinant EPF (rEPF) in Escherichia coli and
have used this tool to investigate the ability of the recombi-
nant molecule to prolong survival time of allogeneic skin
graft in rats. Following skin grafts from Lewis rats, rEPF was
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delivered locally at the graft site to DA rats, and vice versa,
and the effect on survival time of the allografts noted.
Materials and Methods
Animals
Inbred male Lewis and DA rats (approximate weight 100 g), inbred
mature BALB/c mice and outbred mature male Quackenbush mice
were obtained from the Central Animal Breeding House, The Uni-
versity of Queensland. Animals were maintained on a continuous
supply of mouse/rat pellets and water, in temperature- (22–26°C) and
light- (12 h light, 12 h dark) controlled rooms. Investigations were
carried out in accordance with Australian National Health and
Medical Research Committee guidelines with ethical clearance from
The University of Queensland Animal Experimentation Ethics
Committee.
Recombinant EPF
Early pregnancy factor was produced as an in-frame fusion at the 
C-terminus of glutathione S-transferase (GST) using the pGEX-2T
(Amersham Pharmacia Biotech, Uppsala, Sweden) expression
system. The BamHI–EcoRI fragment of pRM3,13 containing the
complete open reading frame of human EPF, was ligated into 
equivalent sites in pGEX-2T and this construct was used to trans-
form DH5 a competent cells. Transformed cells were grown, induced
with isopropyl b -D-thiogalactose (IPTG) and lysed using standard
conditions.14 The GST fusion protein was recovered from the cell
lysate (6 L original culture) with 10 mL glutathione-Sepharose 4B
gel (Amersham Pharmacia Biotech). Following extensive washing of
the gel, rEPF was cleaved from the immobilized fusion protein by
thrombin (750 units thrombin (T6884; Sigma-Aldrich, St Louis, MO,
USA) in 1 mL 0.05 mol/L Tris-HCl pH 8.0/0.15 mol/L NaCl/
2.5 mmol/L CaCl
2 
(Tris/Ca buffer)) and recovered in the supernatant
and three subsequent washes of the gel with 3 mL Tris/Ca
buffer/wash (sample 1). A control buffer (buffer 1) was prepared,
containing 750 units thrombin/10 mL Tris/Ca buffer. The gel was
washed with 4 mL high-salt buffer (0.05 mol/L Tris-HCl pH
8.0/2 mol/L NaCl; buffer 2) and supernatant containing rEPF recov-
ered (sample 2). Samples were stored frozen at –30°C and thawed
only once. Prior to injection, sample 1 and buffer 1 were diluted in
0.15 mol/L NaCl/1% normal syngeneic rat serum, as appropriate.
Sample 2 and buffer 2 (plus 1% rat serum) were exchanged into
saline/1% rat serum on a NAP5 column (Amersham Pharmacia
Biotech) before dilution.
Protein concentration was estimated by the Bradford method
(Bio-rad Protein Assay, Richmond, CA, USA) with bovine serum
albumin as the standard. Purity of preparations was determined by
SDS-PAGE in 15% midget gels (10 · 8 · 0.75 mm) using a Tris-
HCl/Tris-Tricine discontinuous buffer system. N-terminal amino
acid sequencing was performed by the Department of Biochemistry,
The University of Queensland, using an Applied Biosystems Model
470A gas-phase sequencer. Electrospray mass spectrometry was 
performed by the Centre for Drug Design and Development, The
University of Queensland, with a PESCIEX API III triple quadripole
mass spectrometer.
Native EPF
Native EPF (nEPF) was purified from platelets, harvested from 
clinically outdated human blood, as previously described.11 This 
molecule is N-terminally acetylated. The average yield was 15 µg
EPF from approximately 50 L blood.
Synthetic EPF and EPF-derived peptides
Synthetic acetylated and non-acetylated EPF (sAcEPF and sEPF)
and bioactive EPF-derived peptides, corresponding to the 
N-terminus (Ac1–11; AcAGQAFRKFLPL; N-peptide11) and an
internal amino acid sequence (34–44; EKSQGKVLQAT; 
I-peptide11), were synthesized by stepwise solid-phase techniques.15
The peptides had an additional cysteine (C) added to the C terminal
end to facilitate conjugation to ovalbumin in preparation of anti-
bodies in studies described elsewhere.16
Rosette inhibition test: Bioassay for EPF
Early pregnancy factor (0.5 mL, 100 µg/mL in PBS/0.01%
(mass/vol.) BSA) was exchanged into 1.0 mL Hank’s balanced salt
solution/0.01% BSA (HBSS/BSA) on a NAP5 column (final con-
centration rEPF 50 µg/mL (5 µmol/L)). The EPF-derived peptides
(5 µg) were dissolved in 1.0 mL HBSS/BSA (5 µmol/L). Samples
were diluted 10-fold in HBSS/BSA from 10–5 to 10–15 and the rosette
inhibition titre (RIT) of each dilution determined using spleen cells
from Quackenbush mice, as described previously.17 The EPF titre
(log reciprocal sample dilution) was recorded as the highest dilution
of a sample to give a positive result in the assay.
Time course of rEPF in serum following i.p. injection into
mice
Following i.p. injection of rEPF (1.0 or 15.0 µg/mouse), nEPF,
sAcEPF or sEPF (1.0 µg/mouse), N-peptide or I-peptide (0.1 µg/
mouse) in saline/1% BALB/c mouse serum into BALB/c mice, the
time course of activity in serum was determined by the rosette 
inhibition test.17 One of each of these preparations was administered
to a group of three mice and animals were bled from the tail vein at
various times after injection (see Fig. 2). Serum was harvested, inac-
tivated at 56°C for 0.5 h, frozen in small volumes at –30°C and
thawed once only. Samples were tested in the rosette inhibition test
and EPF titre determined. The half-life of EPF activity in serum was
defined as the time after injection when serum EPF titre gave a 50%
decrease in log value compared with that at 0.25 h.
Allogeneic skin grafts
Skin grafts were exchanged between Lewis and DA rats. Rats were
anaesthetized with Nembutal (pentobarbitone sodium, Merial Aust-
ralia, Parramatta, NSW, Australia; 6 mg/100 g bodyweight), shaved,
full-thickness skin (1.3 cm diameter) removed from the abdomen and
sutured into a similar-sized defect created in the lateral thoracic
region. Each rat received two grafts, one allograft and one isograft
(control of technique), one on either side of the thorax. Six rats were
grafted in one session, with two Lewis and two DA rats receiving
rEPF (1 µg, 5 µg, 20 µg or 70 µg/rat per 12 h in 0.25 mL saline/1%
rat serum). One Lewis and one DA rat received vehicle alone.
Recombinant EPF or vehicle was delivered with a 29 gauge needle
at multiple sites around the graft. Treatment continued for 14 days.
Six rats/rEPF dose were grafted in the DA to Lewis series and five
rats/rEPF dose in the Lewis to DA series with the exception of
groups receiving 70 µg rEPF/dose (two rats/group). Grafts were
covered with Sofra-tulle strip (Roussel Laboratories, Uxbridge, UK),
followed by Melolin dressing (Smith + Nephew, Clayton, Vic., Aust-
ralia), held in place with Co-flex cohesive flexible bandage (Andover
Coated products, Salisbury, MA, USA). After 7 days, grafts were
examined daily for signs of necrosis. Day of rejection was taken as
that on which 50% of transplanted skin had undergone necrotic
degradation. The sEPF and nEPF were not tested in this assay.
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Statistical analysis
Student’s t-test was used for comparison of paired and unpaired 
measurements. Time to graft rejection was compared using the
logrank statistic. The 0.05 level of significance was used throughout.
Results
Recombinant EPF
Average yield was 0.3–0.4 mg rEPF/L of culture, with the
majority of rEPF in sample 1. Both samples 1 and 2 had a
high level of purity (85–90% and 90–95%, respectively). 
N-terminal amino acid sequencing of material, following
reversed phase (RP)-HPLC purification, gave the sequence
GSMAGQAF, confirming fidelity of the thrombin cleavage
reaction and the expected addition of GS from the thrombin
cleavage site, as well as the initiating M residue at the 
N-terminus of the recombinant protein. The molecule is not
N-terminally acetylated. Extremely close agreement of deter-
mined (11077.0) and predicted (11075.5) mass demonstrated
that no unexpected alterations to the protein had arisen in this
expression system and confirmed that only a single protein
species was present.
Biological potency of rEPF
Potency of the recombinant molecule in the rosette inhibition
test (Fig. 1) did not differ from that of the full-length native
molecule, the synthetic molecules (sAcEPF, sEPF) or 
synthetic peptides (N-peptide, I-peptide). Modification of the
N-terminus did not affect biological activity of the protein in
this assay.
Time course of activity in serum following injection i.p.
into mice
In contrast to the above results, the half-life of rEPF activity in
serum (3.2 h) was significantly decreased compared with that
of nEPF (6.2 days), sAcEPF (5.3 days) and sEPF (5.8 days;
P < 0.001; Student’s t-test). Non-acetylation alone was not
responsible, because the active half-life of non-acetylated
sEPF did not differ from that of the acetylated preparation. It
appears that the modified N-terminus of rEPF (additional
GSM) markedly shortened the time course of its activity in
serum when compared with the unmodified molecules (Fig. 2).
This suggestion was supported by the time course of activity of
EPF-derived peptides in serum. The N-terminal peptide has an
active half-life in serum (7.1 days) not significantly different
from that of the native or synthetic molecules, while the 
I-peptide has an activity (3.0 h) similar to that of rEPF 
(P < 0.001; Student’s t-test; data not illustrated).
Allogeneic skin grafts
Recombinant EPF significantly prolonged the survival time
of skin grafts, both DA to Lewis and Lewis to DA, as shown
in Fig. 3. Results showed a bell-shaped dose–response, with
high as well as low doses being relatively ineffective. In both
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Figure 1 Early pregnancy factor (EPF) titre of different prepa-
rations of EPF and EPF-derived peptides. Preparations
(5 µmol/L) were diluted 10-fold from 10–5 to 10–15 and the rosette
inhibition titre (RIT) of each dilution determined. The EPF titre
(log reciprocal sample dilution) was recorded as the highest 
dilution of a sample to give a positive result in the assay. rEPF,
recombinant human EPF; nEPF, native EPF; sAcEPF, synthetic
acetylated EPF; sEPF, synthetic non-acetylated EPF; N-pep, 
N-terminal peptide; I-pep, internal peptide.
Figure 2 Time course of early pregnancy factor (EPF) activity
in serum following injection i.p. of various preparations into
BALB/c mice. Recombinant human EPF (1 µg (s) or 15 µg (d)),
native EPF (j), synthetic acetylated EPF (h) or synthetic non-
acetylated EPF (m; 1 µg) were injected i.p. into male BALB/c
mice (three mice/group). Mice were bled from the tail vein on the
days indicated and the EPF titre in serum determined by the
rosette inhibition test.
series of experiments, the most effective doses ranged
between 5 and 20 µg rEPF/rat per 12 h. Median time to rejec-
tion (TTR) was 9 days with grafts receiving vehicle alone,
while median TTR was 14 days in Lewis to DA grafts and
15.5 days in DA to Lewis grafts treated with doses of 5 µg
(P = 0.03 and 0.02, respectively, logrank statistic). Median
TTR was 13.5 days in DA to Lewis grafts and 15.5 days in
Lewis to DA grafts treated with doses of 20 µg (P = 0.008
and 0.05, respectively, logrank statistic).
Discussion
Recombinant EPF was shown to be as active as nEPF and
sEPF within the semiquantitative limits of the rosette inhibi-
tion test. Modification of the N-terminus of the recombinant
molecule did not appear to affect its functional activity in this
assay. N-peptide and the I-peptide gave similar results,
demonstrating that there are a number of active sites within
the molecule. The modified N-terminus did, however, affect
the active half-life of the molecule in serum following i.p.
injection. During early pregnancy, EPF is present in serum in
multiple size forms. The large molecular weight form
( ‡ 250 kDa) apparently originates through association of
smaller forms with a carrier protein or proteins.4 The present
studies suggest that the long half-life of nEPF and sEPF
activity in serum is due to the ability of these molecules to
bind to serum carrier proteins through the N-terminus and
alterations to the N-terminal sequence of rEPF abrogate this
binding. This suggestion is supported by the time course 
of activity of the EPF-derived peptides in serum. The 
N-terminal peptide has an active half-life in serum not 
significantly different from that of the native and synthetic
molecules, while that of the I-peptide is similar to the recom-
binant molecule.
Treatment with EPF significantly prolonged viability of
MHC class I and class II disparate allografts. The results
demonstrated that in suppressing graft rejection, rEPF
demonstrated a bell-shaped dose–response. This phenome-
non has also been observed in the rosette inhibition test, with
high as well as low doses giving a negative response.18 The
reason for this loss of responsiveness is not known, but it may
reflect aggregation of the molecule above certain concentra-
tions with consequent loss of biological activity. While insuf-
ficient recombinant material was available to continue EPF
treatment beyond 14 days after grafting, the results presented
here showed a significant prolongation of survival time in
both the stringent models tested. This is the first report of the
immunomodulatory activity of human EPF in suppressing
graft rejection. Studies are now underway to test the effec-
tiveness of the N-peptide in these models.
Because rEPF has a short half-life in serum, EPF was
administered to the rats subcutaneously around the site of the
graft.19 This route of delivery would ensure that effective 
concentrations of rEPF were administered locally to control
immunological events occurring at the graft site and in the
draining lymph nodes. It is widely believed that donor den-
dritic cells (DC) sensitize the recipient to graft antigens and
initiate the rejection process.19 Donor-derived DC migrate
from the graft into the recipient’s spleen where they associ-
ate with and activate resting CD4+ T cells. In addition, 
epidermal Langerhans cells (LC) migrate from allogeneic
skin grafts, delivering donor LC into the recipient’s nodes,
providing a powerful stimulus for initiation of rejection.20
We have not yet studied the effect of EPF on cells of the
DC lineage, but preliminary studies by Athanasas-Platsis
(unpubl. data, 1999) have shown that a population (28%) of
monocytes from peripheral human blood bind EPF. Other
studies by Athanasas-Platsis and coworkers (unpubl. data,
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Figure 3 Skin grafts were exchanged between DA and Lewis rats. Significant prolongation of median time to rejection (TTR) was
observed following delivery of recombinant human early pregnancy factor (rEPF) subcutaneously around the site of the graft. Full thick-
ness abdominal skin was grafted on to a similar-sized defect on the lateral thoracic region and rats received twice daily injections of
various doses of EPF around the graft site for 14 days. Day of rejection was that on which 50% of transplanted skin had undergone necrotic
degradation. (a) DA skin grafted to Lewis rats. Time to rejection for vehicle alone, 9 days; 5 µg rEPF/dose, 15.5 days (P = 0.02);
20 µg/dose, 13.5 days (P = 0.008). (b) Lewis skin grafted to DA rats. Time to rejection for vehicle alone, 9 days; 5 µg rEPF/dose, 14 days
(P = 0.03); 20 µg rEPF/dose, 15.5 days (P = 0.008). P values were determined by logrank statistics.
1999) have shown that EPF suppresses Th1 responses. Early
pregnancy factor binds to a subpopulation of CD4+ T cells
and, in so doing, suppresses IFN- g production by activated
cells. Partial characterization of cloned CD4+ EPF-binding
cells has shown that they are of the T helper/inducer pheno-
type. Allogeneic skin grafts are known to induce activation of
Th1 cells with the production of IL-2 and IFN- g and prolon-
gation of graft survival is associated with downregulation of
Th1-activated cells, with the immune response being driven
towards a Th2 bias. We postulate that EPF prolongs the 
survival time of allogeneic skin grafts by downregulating
immunostimulation of CD4+ T cells. Whether it also has an
effect on migration of antigen-presenting cells of the den-
dritic lineage has yet to be determined.
The recombinant EPF was effective in significantly pro-
longing the survival time of allogeneic skin grafts. However,
in a standard lymphocyte proliferation assay in vitro and in
the treatment of rats with experimental autoimmune
encephalomyelitis in vivo, we have shown that rEPF is less
active than sEPF (B Zhang et al., unpubl. data, 1999). We are
now preparing a recombinant molecule in insect cells, using
the baculovirus expression system. This will produce an
unmodified form of EPF including N-terminal acetylation
and may provide a more appropriate molecule for further
extensive studies in skin and organ transplant models.
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